Month: September 2024

Ra’anana, Israel, Sept. 05, 2024 (GLOBE NEWSWIRE) — Rail Vision Ltd. (Nasdaq: RVSN) (the “Company”), a technology company at the forefront of revolutionizing railway safety and the data-related market, recently announced the approval of its U.S. patent for a cutting-edge AI-based railway obstacle detection system by the United States Patent and Trademark Office in August. This milestone reflects Rail Vision’s unwavering commitment to advancing railway safety through revolutionary technology, poised to reshape the industry. The newly patented system combines advanced electro-optical imaging with artificial intelligence, offering innovative protection against obstacles on and off rail tracks. Through advanced AI algorithms, including deep learning and convolutional neural networks, the system provides real-time analysis of the railway...

PITTSBURGH, Sept. 05, 2024 (GLOBE NEWSWIRE) — Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, is scheduled to deliver a virtual presentation and host investor one-on-one meetings at the H.C. Wainwright 26th Annual Global Investment Conference, which is being held September 9th through 11th in New York, NY. Management’s presentation will be available on-demand beginning on Monday, September 9th at 7:00 am (ET) via the conference platform. The Predictive Oncology management team will host one-on-one meetings during the conference. Interested investors should contact their H.C. Wainwright representative to request a meeting. About Predictive Oncology Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug...

DENVER, Sept. 05, 2024 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11, 2024 at 9:00 a.m. Eastern time. A webcast of the fireside chat will be available on the Events and Presentations section of the Company’s website. Management is available for in-person and virtual one-on-one meetings throughout the conference being held September 9-11. Institutional investors and industry professionals can register to attend the conference virtually or in-person at the Lotte New York Palace Hotel. About SeaStar Medical SeaStar Medical...

MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) — via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing novel therapies for neurodegenerative diseases, today announced that Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio, will participate in the H.C. Wainwright 26th Annual Global Investment Conference, held both virtually and in person at the Lotte New York Palace Hotel in New York City, September 9-11, 2024. Event Details Company Presentation:Date: Tuesday, September 10, 2024 Time: 8:00 – 8:30 a.m. Eastern Time (ET)Panel Participation:Topic: “Non-amyloid Approaches in Alzheimer’s Disease” Date: Tuesday, September 10, 2024 Time: 2:00 – 3:00 p.m. ETDuring the Company presentation, Dr. Maccecchini will provide...

Planegg/Martinsried, September 5, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for its lead program MDG1015 for the treatment of advanced gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma in the phase 1 clinical trial (EPITOME1015-I) . EPITOME1015-I consists of a dose escalation followed by an expansion segment and aims to assess safety, feasibility and preliminary efficacy of MDG1015 in multiple solid tumor indications. “We are very excited to reach this milestone with our lead program MDG1015 which reinforces...

Strategic leadership change will drive further growth and expansion among core business units NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) — XWELL, Inc. (Nasdaq: XWEL) (“XWELL” or the “Company”), an authority in wellness solutions for people on the go, today announced the appoint of Ezra T. Ernst as Chief Executive Officer. Ernst succeeds Scott Milford, who will serve in a consultative role through the end of 2024. “Ezra brings the combination of operational and strategic excellence to the position, while also having a deep understanding of the company, the industry and key partners,” said XWELL Chairman of the Board, Bruce Bernstein. “This strategic leadership change will propel XWELL forward in its next phase. I trust that Ezra will deliver purpose-driven growth for XWELL through continued innovation and expansion, ultimately returning...

TransUnion’s Q3 2024 Credit Union Market Perspectives Report explores the current state of consumer credit and its impact on credit unions CHICAGO, Sept. 05, 2024 (GLOBE NEWSWIRE) — The newly released Q3 2024 Credit Union Market Perspectives Report from TransUnion (NYSE: TRU) found that balances continue to rise across all credit products, led by share growth among consumers in the super prime and subprime risk tiers. Among credit unions, balances grew among all consumer lending areas in Q2 2024. Growth ranged from 2.7% in credit union auto balances up to 14.4% for home equity loan balances as borrowers continue tapping into the equity in their home to make home improvements, consolidate other debt, or pay for other large purchases, like education expenses. Bankcards also saw significant YoY balance growth, up 8.6% over the period. “Despite...